Accolade Inc. (ACCD) News
Filter ACCD News Items
ACCD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACCD News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ACCD News From Around the Web
Below are the latest news stories about ACCOLADE INC that investors may wish to consider to help them evaluate ACCD as an investment opportunity.
Accolade (ACCD) Reports Q3 Loss, Lags Revenue EstimatesAccolade (ACCD) delivered earnings and revenue surprises of 3.23% and 0.89%, respectively, for the quarter ended November 2024. Do the numbers hold clues to what lies ahead for the stock? |
Accolade: Fiscal Q3 Earnings SnapshotSEATTLE (AP) — Accolade, Inc. ACCD) on Friday reported a loss of $121.3 million in its fiscal third quarter. On a per-share basis, the Seattle-based company said it had a loss of $1.50. |
Transcarent to acquire health advocacy and primary care company Accolade for $621mThe acquisition has been unanimously approved by both companies' boards. |
Accolade to be acquired by Transcarent for $7.03 per share in cashTranscarent, the One Place for Health and Care, and Accolade (ACCD) announced that they have entered into a definitive agreement under which Transcarent will acquire Accolade for $7.03 per share in cash, which represents a total equity value of approximately $621M. This strategic combination, which has been unanimously approved by the Boards of Directors of both companies, will enhance Transcarent’s mission to make it easy for people to access high-quality, affordable health and care. The combin |
Accolade Q3 2025 Earnings PreviewMore on Accolade |
Accolade to be Acquired, Taken Private by Transcarent in $621 Million DealAccolade (ACCD) agreed to be acquired and delisted by Transcarent in a $621 million deal that's expe |
Transcarent To Acquire AccoladeCombined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent’s Generative AI WayFinding and care experiences combined with Accolade’s Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care’ Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and |
Transcarent to acquire fellow health benefits navigator Accolade for $621MIf closed, the deal will take Accolade private and create a single firm with more than 1,400 employer and payer clients. |
Accolade to Announce Fiscal Third Quarter 2025 Financial ResultsSEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/regis |
Accolade (ACCD) Upgraded to Buy: Here's WhyAccolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |